An interventional study of real-time CGM in Diabetes Mellitus Type 2, sponsored by Shanghai 6th People's Hospital. Recruiting at 21 sites in China. Open to participants aged 60 Years and older. Per ClinicalTrials.gov, last updated 2026-09-08.
Sponsored by Shanghai 6th People's Hospital · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies in Diabetes Mellitus, Type 2 by Shanghai 6th People's Hospital — 6 open to participants now, 7 under way, none of them phase 3. Diabetes Mellitus, Type 2 · Shanghai 6th People's Hospital.
Among the 11 studies in Diabetes Mellitus, Type 2 by Shanghai 6th People's Hospital, this one is one of 4 that started in 2025, is one of 7 with no phase, and was the 7th registered.
10,403 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →6 of the 11 studies in Diabetes Mellitus, Type 2 by Shanghai 6th People's Hospital are open now, in 1 country. Recruiting first, the newest first:
Shanghai 6th People's Hospital · Sites in China
Ages 18–80
Shanghai 6th People's Hospital · Sites in China
Ages 35–70
Shanghai 6th People's Hospital · Sites in China
Ages 18–70
Shanghai 6th People's Hospital · Sites in China
Ages 18–80
Shanghai 6th People's Hospital · Sites in China
Ages 18–80
By country, each count listing its studies:
Of the 882 Diabetes Mellitus, Type 2 studies recruiting now, 372 (42%) set no upper age limit and 384 (44%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.
This study: 60 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
First in 2014; this study’s year is marked. 4 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 148 is above the median of 80 across 8,372 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 150 across the 8 interventional studies, 225 across the 3 observational. Of the 2 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Shanghai 6th People's Hospital is the lead sponsor of 70 studies on the registry; 39 are open to participants now.
5 of the studies in Diabetes Mellitus, Type 2 by Shanghai 6th People's Hospital that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07007676Shanghai 6th People's HospitalEffect of Continuous Glucose Monitoring System on Glycemic Control in Non-insulin-Treated Elderly People With Type 2 Diabetes | 2027-02-28 |
| NCT06936657Shanghai 6th People's HospitalIntervention Effects of Optimized Carbohydrate Diet in Patients With Type 2 Diabetes | 2027-06-30 |
| NCT07288372Shanghai 6th People's HospitalThe CGM-OGTT Glycemic Homeostasis Study | 2027-06-30 |
| NCT07156370Shanghai 6th People's HospitalSalivary Cortisol and Hypercortisolism in Type 2 Diabetes | 2027-06-30 |
| NCT07414277Shanghai 6th People's HospitalCGM for Insulin-Treated T2DM During Post-Discharge Transition | 2027-09-30 |
Add all 5 to your calendar (.ics) → With an account.
Among the 11 studies in Diabetes Mellitus, Type 2 by Shanghai 6th People's Hospital, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this clinical trial is to learn if continuous glucose monitoring system works to improve glucose control in non-insulin-treated older adults with type 2 diabetes. The main questions it aims to answer are:
Participants will:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CGM group participants will be asked to use a CGM sensor every 2 months. Participants will be instructed to use the sensor. In addition, participants will be advised to check the blood glucose when symptoms or expectations do not match the CGM reading.
Device: real-time CGM
BGM group participants will be asked to use a study blood glucose meter with test strips for a fingerstick blood glucose check with a recommendation of 2 times a week. Participants will be permitted to check a fingerstick glucose as many times a week as they choose.
real-time CGM can provide real-time tracking of glucose levels, and offer glucose trend graphs and user-configurable low and high glucose alerts.
Also known as: rtCGM, RT-CGM
Change in HbA1c
Change in HbA1c from baseline to 24 weeks
Time frame: 24 weeks from baseline
Time in range of 70-180 mg/dL
A treatment group comparison of percentage of time spent in glucose range between 70 and 180 mg/dL measured by CGM
Time frame: 24 weeks from baseline
Time below range of 70 mg/dL
A treatment group comparison of percentage of time spent in glucose range below 70 mg/dL measured by CGM
Time frame: 24 weeks from baseline
Time above range of 180 mg/dL
A treatment group comparison of percentage of time spent in glucose range above 180 mg/dL measured by CGM
Time frame: 24 weeks from baseline
Glucose coefficient of variability
A treatment group comparison of glucose coefficient of variability measured by CGM
Time frame: 24 weeks from baseline
Mean glucose
A treatment group comparison of the mean glucose measured by CGM
Time frame: 24 weeks from baseline
HbA1c <7.0%
Percentage of subjects with A1C less than 7%
Time frame: 24 weeks from baseline
Reduction in HbA1c ≥0.5%
Percentage of subjects with a reduction in A1C greater than or equal to 0.5%
Time frame: 24 weeks from baseline
Rate of hypoglycemia events per week
Hypoglycemia event was defined as 15 consecutive minutes with a sensor glucose value \<70 mg/dL
Time frame: 24 weeks from baseline
Time in tight range of 70-140 mg/dL
A treatment group comparison of the percentage of time spent in glucose range between 70 and 140 mg/dL measured by CGM
Time frame: 24 weeks from baseline
Glycemia risk index (GRI)
A treatment group comparison of the glycemia risk index measured by CGM. Glycemia risk index (GRI) was calculated according to the following equation: GRI = (3.0×VLow) + (2.4×Low) + (1.6×VHigh) + (0.8×High).
Time frame: 24 weeks from baseline
Glucose standard deviation
A treatment group comparison of the glucose standard deviation measured by CGM
Time frame: 24 weeks from baseline
Days to initiate inulin treatment
A treatment group comparison of the days to initiate inulin treatment during study period
Time frame: 24 weeks from baseline
Change in the scores of psychological-related questionnaires
Psychological-related events were measured by Diabetes Distress Scale and Patient Health Questionnaire-8 items.
Time frame: 24 weeks from baseline
Change in the score of blood glucose monitoring satisfaction questionnaire
Change in the score of blood glucose monitoring satisfaction questionnaire from 24 weeks from baseline
Time frame: 24 weeks from baseline
Plan to share: No
No publications or documents are linked to this record.
Started Jul 2025 (actual). Primary completion is estimated for Feb 2027, 19 months after the start.
Of 2,078 non-industry interventional studies with no phase under Diabetes Mellitus, Type 2, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 40. This study's planned 19 months is close to that.
Counting every sponsor, half of 2,255 studies reached it within 21 months; a quarter within 10 and three quarters within 39.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Shanghai 6th People's Hospital